Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 6/20 | 0.48 |
| ▸ | NAMPT | P43490 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.40 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6351436 | 1.00 | DRD4 (0.48) | DRD4NAMPTCYP2C9EPHX2TMEM97 | |
| SCHEMBL6351385 | 0.89 | NAMPT (0.46) | DRD4NAMPTCYP2C9EPHX2TMEM97 | |
| SCHEMBL6351170 | 0.89 | NAMPT (0.46) | DRD4NAMPTCYP2C9EPHX2TMEM97 | |
| SCHEMBL6351165 | 0.89 | NAMPT (0.46) | DRD4NAMPTCYP2C9EPHX2TMEM97 | |
| SCHEMBL6351409 | 0.87 | DRD4 (0.52) | DRD4NAMPTCYP2C9EPHX2PDCD1LG2 | |
| SCHEMBL6351411 | 0.87 | DRD4 (0.52) | DRD4NAMPTCYP2C9EPHX2PDCD1LG2 | |
| SCHEMBL6351565 | 0.87 | DRD4 (0.52) | DRD4NAMPTCYP2C9EPHX2PDCD1LG2 | |
| SCHEMBL6356442 | 0.84 | CYP2C9 (0.54) | NAMPTCYP2C9EPHX2TMEM97SIGMAR1 | |
| SCHEMBL6349712 | 0.79 | DRD4 (0.58) | DRD4NAMPTCYP2C9EPHX2DRD2 | |
| SCHEMBL6352358 | 0.79 | DRD4 (0.58) | DRD4NAMPTCYP2C9EPHX2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2005-08-11 | — | — | US | claimed |
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | CYP19A1, SHBG, CYP17A1 | DRD4 1272/4885NAMPT 2899/4885CYP2C9 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.